CA
NZ
UK
AU
IND
US
…
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -266.46M | -562.38M | -618.01M | -790.15M | -555.44M |
| Net income | -266.58M | -562.64M | -618.70M | -789.61M | -555.62M |
| Selling general administrative | 136.91M | 209.97M | 286.90M | 271.36M | 174.13M |
| Gross profit | -6.48M | -35.20M | 245.34M | 41.70M | 53.69M |
| Reconciled depreciation | 5.00M | 19.65M | 19.36M | 17.43M | 17.16M |
| Ebit | -287.09M | -590.91M | -629.51M | -812.08M | -583.18M |
| Ebitda | -277.21M | -539.31M | -635.98M | -809.33M | -566.02M |
| Depreciation and amortization | 9.88M | 51.60M | -6.47M | 2.75M | 17.16M |
| Non operating income net other | - | 27.65M | -6.50M | -10.09M | 1.96M |
| Operating income | -287.09M | -590.91M | -629.51M | -812.08M | -572.02M |
| Other operating expenses | 285.75M | 568.77M | 880.25M | 856.75M | 623.60M |
| Interest expense | -20.63M | 260.16M | 37.33M | 34.76M | 14.62M |
| Tax provision | 0.12M | 0.26M | 0.69M | -0.55M | 0.19M |
| Interest income | 1.03M | 0.88M | 11.54M | 34.76M | 14.62M |
| Net interest income | 1.03M | 0.88M | 11.54M | 34.76M | 14.62M |
| Non recurring | - | 25.80M | - | - | - |
| Income tax expense | 0.12M | 0.26M | 0.69M | -0.55M | 0.19M |
| Total revenue | 3.60M | 3.66M | 250.73M | 44.67M | 54.58M |
| Total operating expenses | 275.67M | 529.91M | 874.85M | 853.77M | 622.72M |
| Cost of revenue | 10.08M | 38.86M | 5.40M | 2.98M | 0.89M |
| Total other income expense net | 20.63M | 28.53M | 11.51M | 21.93M | -1.04M |
| Discontinued operations | - | -256.74M | -256.74M | -256.74M | -256.74M |
| Net income from continuing ops | -266.58M | -562.64M | -618.70M | -789.61M | -555.62M |
| Net income applicable to common shares | -266.58M | -819.38M | -618.70M | -789.61M | -555.62M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 619.16M | 554.90M | 593.79M | 1781.25M | 1727.42M |
| Intangible assets | 10.44M | 4.87M | 5.64M | 10.04M | 14.33M |
| Other current assets | - | 8.37M | 37.02M | 64.29M | 45.71M |
| Total liab | 424.62M | 358.56M | 219.52M | 426.20M | 442.43M |
| Total stockholder equity | 194.54M | 196.34M | 374.28M | 1355.06M | 1284.99M |
| Other current liab | 9.04M | 50.48M | 101.68M | 145.41M | 141.56M |
| Common stock | - | 0.83M | 0.71M | 0.67M | 0.55M |
| Capital stock | 1.91M | 0.83M | 0.71M | 0.67M | 0.55M |
| Retained earnings | -4260.33M | -3986.50M | -3719.93M | -2900.55M | -2281.85M |
| Other liab | - | - | 0.09M | 54.61M | 48.04M |
| Good will | 5.65M | 5.65M | 5.65M | 13.13M | 13.13M |
| Other assets | - | 52.13M | 53.28M | 72.81M | 79.23M |
| Cash | 221.75M | 113.01M | 161.16M | 317.70M | 327.21M |
| Total current liabilities | 200.11M | 128.24M | 152.99M | 203.59M | 223.58M |
| Current deferred revenue | - | 1.50M | 2.28M | 11.56M | 18.85M |
| Net debt | - | 168.38M | -71.58M | -124.68M | -136.23M |
| Short term debt | - | 51.16M | 23.15M | 25.02M | 20.18M |
| Short long term debt total | - | 281.39M | 89.58M | 193.02M | 190.99M |
| Other stockholder equity | - | 4186.09M | 4096.40M | 4260.44M | 3568.18M |
| Property plant equipment | - | 291.36M | 101.24M | 162.83M | 151.18M |
| Total current assets | 281.69M | 199.49M | 336.52M | 1215.54M | 1152.17M |
| Long term investments | 0.00M | 1.41M | 97.11M | 122.89M | 131.51M |
| Net tangible assets | - | 185.83M | 368.63M | 1331.89M | 1257.54M |
| Short term investments | 0.00M | 67.32M | 138.34M | 833.55M | 779.25M |
| Net receivables | 22.21M | 10.79M | 11.39M | 26.81M | 12.83M |
| Inventory | 22.92M | -1.41M | -108.50M | -149.71M | -144.33M |
| Accounts payable | 18.50M | 25.09M | 25.88M | 21.60M | 42.99M |
| Accumulated other comprehensive income | - | -4.07M | -2.91M | -5.50M | -1.89M |
| Common stock total equity | - | - | 0.71M | 0.67M | 0.55M |
| Retained earnings total equity | - | - | -3719.93M | -2900.55M | -2281.85M |
| Non currrent assets other | 54.34M | 52.13M | 53.28M | 72.81M | 79.23M |
| Non current assets total | 337.48M | 355.41M | 257.27M | 565.72M | 575.25M |
| Capital lease obligations | 330.33M | 281.39M | 89.58M | 193.02M | 190.99M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 250.45M | 475.26M | -55.36M | 584.06M | -623.70M |
| Change to liabilities | 0.00M | 9.29M | -25.08M | 69.89M | 41.45M |
| Total cashflows from investing activities | 250.45M | 562.56M | -84.34M | 507.81M | -679.43M |
| Net borrowings | - | - | - | - | -1.02M |
| Total cash from financing activities | 54.25M | -93.95M | 546.72M | 21.19M | 737.69M |
| Change to operating activities | -30.98M | 27.15M | -18.57M | 39.19M | 57.50M |
| Net income | -266.58M | -819.38M | -618.70M | -789.61M | -555.62M |
| Change in cash | -48.25M | -167.04M | -7.98M | -35.39M | -355.17M |
| Begin period cash flow | 206.69M | 373.73M | 381.71M | 417.10M | 772.27M |
| End period cash flow | 158.44M | 206.69M | 373.73M | 381.71M | 417.10M |
| Total cash from operating activities | -352.95M | -635.64M | -470.35M | -564.38M | -413.43M |
| Issuance of capital stock | 54.24M | 74.97M | 541.54M | 0.00M | 703.85M |
| Depreciation | 5.00M | 19.65M | 19.36M | 17.43M | 17.16M |
| Other cashflows from investing activities | 102.00M | 101.80M | 102.00M | -5.22M | -623.70M |
| Dividends paid | - | 174.28M | - | - | - |
| Change to inventory | -7.23M | -18.45M | -18.45M | -18.45M | -18.45M |
| Change to account receivables | - | 32.74M | 1.50M | - | - |
| Sale purchase of stock | - | 80.33M | 546.72M | 21.19M | 681.13M |
| Other cashflows from financing activities | 0.02M | -168.93M | 5.18M | 21.19M | 34.86M |
| Change to netincome | -52.25M | 146.10M | 150.62M | 149.63M | 104.96M |
| Capital expenditures | 13.21M | 23.00M | 28.99M | 76.25M | 55.74M |
| Cash flows other operating | - | -42.23M | 3.45M | -11.73M | -21.36M |
| Cash and cash equivalents changes | - | -167.04M | -7.98M | -35.39M | -355.17M |
| Change in working capital | -39.12M | 17.98M | -28.85M | 46.12M | 19.24M |
| Stock based compensation | 35.19M | 127.92M | 156.63M | 160.63M | 110.84M |
| Other non cash items | -87.44M | 17.62M | -6.01M | -8.25M | -2.88M |
| Free cash flow | -366.16M | -658.64M | -499.34M | -640.64M | -469.16M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.79 2.05% |
39.08 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
14.65 2.77% |
544.34 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
7.93 0.98% |
821.20 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
455 Grand Union Boulevard, Somerville, MA, United States, 02145
339 499 9300
375
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew Obenshain | Pres, CEO & Director | 1975 |
| Mr. Thomas J. Klima | Chief Commercial Officer & COO | 1972 |
| Mr. Christopher Krawtschuk CPA | CFO, Principal Accounting Officer & Treasurer | 1974 |
| Ms. Elizabeth Pingpank | Director of Corp. Communications | NA |
| Sarah Alspach | Chief Communications Officer | NA |
| Ms. Andrea Walton | Chief People Officer | NA |
| Dr. Liviu Niculescu M.D., Ph.D. | Sr. VP of Global Medical Affairs | NA |
| Ms. Melissa Bonner | Sr. VP of Research | NA |
| Mr. Richard Colvin M.D., Ph.D. | Chief Medical Officer | NA |
| Mr. Kasra Kasraian | Sr. VP of Technical Devel. & Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.04%
Communication Services
+0.02%
Consumer Cyclical
+0.67%
Consumer Defensive
-0.22%
Energy
-0.01%
Financial Services
+0.37%
Financials
-0.58%
Healthcare
+0.92%
Industrials
+0.69%
Real Estate
+0.33%
Technology
-0.23%
Utilities
+0.34%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...